--- title: "BeyondSpring | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286247365.md" datetime: "2026-05-13T11:02:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286247365.md) - [en](https://longbridge.com/en/news/286247365.md) - [zh-HK](https://longbridge.com/zh-HK/news/286247365.md) --- # BeyondSpring | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.05. EBIT: As of FY2026 Q1, the actual value is USD -2.24 M. BeyondSpring Inc. (万春药业) announced its financial results for the quarter ended March 31, 2026, as detailed in a press release furnished via a Form 8-K filing . ### First Quarter 2026 Financial Results (Continuing Operations) #### Research and Development (R&D) Expenses For the three months ended March 31, 2026, R&D expenses were - $1.1 million, an increase of $0.2 million compared to - $0.9 million for the three months ended March 31, 2025 . This increase was primarily due to increased drug manufacturing activities for potential future study initiation, partially offset by lower regulatory filing advisory and personnel expenses . #### General and Administrative (G&A) Expenses G&A expenses for the three months ended March 31, 2026, were - $1.1 million, a decrease of $0.6 million from - $1.7 million for the three months ended March 31, 2025 . This decrease was mainly driven by lower personnel and legal advisory expenses . #### Net Loss from Continuing Operations BeyondSpring Inc. (万春药业) reported a net loss of - $2.4 million for the three months ended March 31, 2026, compared to a net loss of - $2.6 million for the three months ended March 31, 2025 . More precisely, the net loss from continuing operations was - $2,351 thousand for the three months ended March 31, 2026, versus - $2,584 thousand for the same period in 2025 . #### Cash, Cash Equivalents, and Short-Term Investments As of March 31, 2026, cash, cash equivalents, and short-term investments totaled $7.9 million . This included cash and cash equivalents of $4,036 thousand and short-term investments of $3,827 thousand . ### First Quarter 2026 Financial Results (Discontinued Operations) #### Net Loss from Discontinued Operations For the three months ended March 31, 2026, net loss from discontinued operations was - $4.3 million . This contrasts with a net income of $3.8 million for the three months ended March 31, 2025, which included a $6,986 thousand gain on sale of subsidiary interests . #### Current Assets of Discontinued Operations As of March 31, 2026, current assets of discontinued operations were $5.3 million . ### Additional Balance Sheet Metrics (as of March 31, 2026 vs. December 31, 2025) #### Total Current Assets Total current assets decreased to $13,504 thousand as of March 31, 2026, from $20,882 thousand as of December 31, 2025 . #### Total Assets Total assets were $18,406 thousand as of March 31, 2026, down from $25,933 thousand as of December 31, 2025 . #### Accounts Payable Accounts payable increased to $646 thousand as of March 31, 2026, from $363 thousand as of December 31, 2025 . #### Accrued Expenses Accrued expenses rose to $1,278 thousand as of March 31, 2026, from $938 thousand as of December 31, 2025 . #### Current Liabilities of Discontinued Operations Current liabilities of discontinued operations decreased to $9,263 thousand as of March 31, 2026, from $11,133 thousand as of December 31, 2025 . #### Total Current Liabilities Total current liabilities were $12,370 thousand as of March 31, 2026, compared to $13,576 thousand as of December 31, 2025 . #### Deferred Revenue Deferred revenue increased slightly to $28,994 thousand as of March 31, 2026, from $28,600 thousand as of December 31, 2025 . #### Total Liabilities Total liabilities decreased to $48,760 thousand as of March 31, 2026, from $49,923 thousand as of December 31, 2025 . #### Accumulated Deficit The accumulated deficit increased to - $410,590 thousand as of March 31, 2026, from - $408,431 thousand as of December 31, 2025 . #### Total Shareholders’ Deficit Total shareholders’ deficit worsened to - $30,354 thousand as of March 31, 2026, from - $23,990 thousand as of December 31, 2025 . ### Additional Income Statement Metrics (Three months ended March 31, 2026 vs. 2025) #### Revenue BeyondSpring Inc. (万春药业) reported no revenue for both the three months ended March 31, 2026, and March 31, 2025 . #### Loss from Operations Loss from operations was - $2,232 thousand for the three months ended March 31, 2026, compared to - $2,610 thousand for the same period in 2025 . #### Foreign Exchange Gain, net Foreign exchange gain, net, was $50 thousand for the three months ended March 31, 2026, up from $29 thousand in the prior year period . #### Interest Income Interest income was $8 thousand for the three months ended March 31, 2026, down from $17 thousand in the prior year period . #### Income Tax Expenses Income tax expenses were - $192 thousand for the three months ended March 31, 2026, compared to - $20 thousand for the same period in 2025 . #### Net Income (Loss) Attributable to BeyondSpring Inc. Net loss attributable to BeyondSpring Inc. (万春药业) was - $2,159 thousand for the three months ended March 31, 2026, a decrease from a net income of $4,477 thousand for the same period in 2025 . #### Comprehensive Income (Loss) Attributable to BeyondSpring Inc. Comprehensive loss attributable to BeyondSpring Inc. (万春药业) was - $2,401 thousand for the three months ended March 31, 2026, compared to a comprehensive income of $4,380 thousand for the same period in 2025 . ### Corporate Update and Outlook BeyondSpring Inc. (万春药业) highlights Plinabulin’s potential as a foundational combination therapy to enhance efficacy and tolerability in ADC-based regimens, aiming to address limitations like durability and safety concerns . The company’s SEED Therapeutics division is advancing ST-01156, a novel molecular glue degrader, into Phase 1 clinical development using a biomarker-driven approach . These milestones reflect disciplined execution and position the company for long-term value through clinical and strategic partnership opportunities . ### Related Stocks - [BYSI.US](https://longbridge.com/en/quote/BYSI.US.md) ## Related News & Research - [BeyondSpring Q2 FY26 net loss narrows to $1.8 million; cash falls to $6.5 million](https://longbridge.com/en/news/295977996.md) - [BeyondSpring posts investor deck highlighting plinabulin late-stage NSCLC program and immune-modulating approach](https://longbridge.com/en/news/296010507.md) - [ADCT: Q2 2026 delivered stable sales, improved losses, and regulatory challenges for ZYNLONTA](https://longbridge.com/en/news/295792223.md) - [Pyxis Oncology posts corporate deck spotlighting MICVO extracellular-targeting ADC in head-and-neck cancer](https://longbridge.com/en/news/295788544.md) - [IPH: Three late-stage oncology assets drive value, with major partnerships and pivotal data due in H2 2026](https://longbridge.com/en/news/295950027.md)